Patent: 11,274,301
✉ Email this page to a colleague
Summary for Patent: 11,274,301
| Title: | Micro-RNA inhibitors and their uses in disease |
| Abstract: | The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs). |
| Inventor(s): | Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena |
| Assignee: | Beth Israel Deaconess Medical Center Inc |
| Application Number: | US15/727,156 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,274,301
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bluebird Bio Inc. | SKYSONA | elivaldogene autotemcel | Injection | 125755 | September 16, 2022 | ⤷ Start Trial | 2037-10-06 |
| Genetix Biotherapeutics Inc. | SKYSONA | elivaldogene autotemcel | Injection | 125755 | 16-Sep-22 | ⤷ Start Trial | 2037-10-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,274,301
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2012242761 | ⤷ Start Trial |
| Brazil | 112013026298 | ⤷ Start Trial |
| Canada | 2832899 | ⤷ Start Trial |
| European Patent Office | 2697374 | ⤷ Start Trial |
| European Patent Office | 3159410 | ⤷ Start Trial |
| Japan | 2014515024 | ⤷ Start Trial |
| United States of America | 10131905 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
